Discover the future of mental health care through the eyes of Tony Budden, CEO of PsyLabs, in his thought-provoking feature in Insights Care Magazine. As a pioneer in the development of nature-derived psychedelic compounds like psilocybin and ibogaine, PsyLabs—working in close partnership with Psyence Biomed—is advancing groundbreaking solutions for substance use disorders and other mental health challenges.
Psyence BioMed announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”). The Staff's determination is based on the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.
Psyence BioMed today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development.
New partnership strengthens Psyence BioMed’s global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant in a private placement.
